Actibrain Overview
- Year Founded
-
2019
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
Actibrain General Information
Description
Developer of a bispecific antibody platform designed to create therapeutic drugs targeting immuno-oncology and neurodegenerative diseases. The company offers a pipeline of drug candidates featuring modular platforms that engage immune receptors and enhance blood-brain barrier penetration, enabling pharmaceutical and medical research sectors to address complex diseases with targeted biologic therapies and advance clinical development.
Contact Information
Website
www.ablab.bioCorporate Office
- 17, Hakdong-ro 28-gil
- Gangnam-gu
- Seoul
- South Korea
Corporate Office
- 17, Hakdong-ro 28-gil
- Gangnam-gu
- Seoul
- South Korea
Actibrain Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Out of Business | 03-Oct-2025 | Completed | Out of Business | |||
| 3. Accelerator/Incubator | 01-Oct-2024 | Completed | Generating Revenue | |||
| 2. Seed Round | 01-Jan-2023 | Completed | Generating Revenue | |||
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Actibrain FAQs
-
When was Actibrain founded?
Actibrain was founded in 2019.
-
Where is Actibrain headquartered?
Actibrain is headquartered in Seoul, South Korea.
-
What industry is Actibrain in?
Actibrain’s primary industry is Other Healthcare Technology Systems.
-
Is Actibrain a private or public company?
Actibrain is a Private company.
-
What is Actibrain’s current revenue?
The current revenue for Actibrain is .
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process